跳转至内容
Merck
CN

主要文件

查看所有文档

SFRVN

Sf-RVN® Insect Cell Line

别名:

Sf9 rhabdovirus-negative (Sf-RVN®) Insect Cell Line

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

UNSPSC Code:
41116105
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

description

Sf9 rhabdovirus-negative (Sf-RVN®) Insect Cell Line

solubility

DMSO: 10%

shipped in

liquid nitrogen

storage temp.

−196°C

General description

Sf-RVN® cells are provided to customers in vials containing 1 mL at 10 x 106 cells/mL. Cells are banked in EX-CELL® CD Insect Cell Medium and 10% DMSO.
The Sf-RVN® Insect Cell Line is a rhabdovirus-negative Sf9 cell line that can be grown in both adherent and suspension culture. Sf-RVN® Insect Cell Line has been adapted for growth in chemically defined medium to be used for the production of recombinant proteins, adeno-associated viruses (AAV) and viral-like particles (VLP). The cell line was tested for adventitious agents and banked under GMP conditions. A technical user guide, with detailed protocols for optimal performances, is provided with the cell line.The EX-CELL® CD Insect Cell Medium, recommended for use, is optimized to get excellent growth and productivity of the Sf-RVN® Insect Cell Line. Combined, these two products form the Sf-RVN® Platform.

Cell Line Origin

Sf-RVN® is an insect cell line originally derived from ovarian tissue of Spodoptera frugiperda (Sf) pupae. The parental line, IPLB-SF-21 (renamed IPLB-SF-21 AE after adaptation into TC-100 medium), was established by J. Vaughn at the Insect Pathology Beltsville in Maryland, USA in the late 1960s. A subclone, designated Sf9, was established in 1983 by G. Smith and C. Cherry. Sf-RVN® was isolated from Sf9 by GlycoBac, LLC.

Physical form

Sf-RVN® cells are provided to customers in vials containing 1 mL at 10 x 106cells/mL. Cells are banked in EX-CELL® CD Insect Cell Medium and 10% DMSO

Other Notes

Sf-RVN® is an insect cell line originally derived from ovarian tissue of Spodoptera frugiperda (Sf) pupae. The parental line, IPLB-SF-21 (renamed IPLB-SF-21 AE after adaptation into TC-100 medium), was established by J. Vaughn at the Insect Pathology Beltsville in Maryland, USA in the late 1960s. A subclone, designated Sf9, was established in 1983 by G. Smith and C. Cherry. Sf-RVN® was isolated from Sf9 by GlycoBac, LLC.

Legal Information

EX-CELL is a registered trademark of Merck KGaA, Darmstadt, Germany
Sf-RVN is a registered trademark of Merck KGaA, Darmstadt, Germany

存储类别

12 - Non Combustible Liquids

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

动物来源生物产品

此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

商品

Can AAV Continue to Deliver the Promise of Gene Therapy?

The current status and future manufacturing of AAV-based gene therapies is discussed in this podcast transcript, including how to streamline large-scale manufacturing.

High Performing Platforms for Lentivirus and AAV Manufacturing

Upstream gene therapy optimization maximizes viral vector titers; partner with technology experts for HEK293, HEK293T, and Sf9 cell solutions.

Cell and Gene Therapy Manufacturing: Upstream Processing for AAV and Lentivirus Platforms

Minimize the complexities of cell and gene therapy production. Switch to upstream viral vector platforms to enhance scalability and simplify GMP manufacturing.

查看所有文章

相关内容

病毒载体上游平台

针对病毒载体生产的转染解决方案采用悬浮细胞系、化学成分明确的培养基以及性能已得到证明的工艺。

Viral Vector Upstream Platforms

A transfection-based solution to viral vector production using a suspension cell line, chemically defined medium, and a process with proven performance at scale.